Trials / Completed
CompletedNCT00838799
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 458 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGH-896 | 45 mg TID, capsules, 14 weeks. |
| DRUG | RGH-896 | 30 mg TID, capsules, 14 weeks. |
| DRUG | RGH-896 | 15 mg TID, capsules, 14 weeks. |
| DRUG | pregabalin | 100 mg, TID, capsules, 14 weeks. |
| DRUG | placebo | TID, capsules, 14 weeks. |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-04-01
- First posted
- 2009-02-06
- Last updated
- 2011-07-14
Locations
54 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00838799. Inclusion in this directory is not an endorsement.